Patents Assigned to Medarex
  • MONOCLONAL ANTIBODIES AGAINST STROMAL DERIVED FACTOR-1 (SDF-1)
    Publication number: 20100158902
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to SDF-1 with high affinity. Nucleic acid molecules encoding SDF-1 antibodies, expression vectors, host cells and methods for expressing the SDF-1 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the SDF-1 antibodies are also provided. Methods for detecting SDF-1, as well as methods for treating various B cell malignancies, including breast cancer, multiple myeloma and non-Hodgkin's lymphoma, and autoimmune disorders are disclosed.
    Type: Application
    Filed: August 10, 2007
    Publication date: June 24, 2010
    Applicants: ONO PHARMACEUTICAL CO., LTD., MEDAREX, INC.
    Inventors: Sarah L. Pogue, Alan J. Korman, Josephine M. Cardarelli, Mohan Srinivasan, Bingliang Chen, Alasdir F. Bell
  • Anti-interferon alpha antibodies
    Patent number: 7741449
    Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: June 22, 2010
    Assignee: Medarex, Inc.
    Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David Passmore
  • HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF
    Publication number: 20100150950
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD70 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human CD70. In certain embodiments, the antibodies are capable of being internalized into CD70-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD70, as well as methods for treating cancers, such as renal cancer and lymphomas, using an anti-CD7Q antibody of this disclosure.
    Type: Application
    Filed: December 13, 2007
    Publication date: June 17, 2010
    Applicant: Medarex, Inc.
    Inventors: Marco A. Coccia, Jonathan A. Terrett, David John King, Chin Pan, Josephine Cardarelli, Mark Yamanaka, Ann Karla Henning
  • CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF
    Publication number: 20100145036
    Abstract: The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
    Type: Application
    Filed: December 28, 2007
    Publication date: June 10, 2010
    Applicant: Medarex, Inc.
    Inventors: Bilal Sufi, Vincent Guerlavais, Liang Chen, Sanjeev Gangwar, Qian Zhang, David B. Passmore
  • Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
    Patent number: 7718776
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: May 18, 2010
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: William J. Boyle, Eugene Medlock, John J. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Cytotoxic compounds and conjugates with cleavable substrates
    Patent number: 7714016
    Abstract: The present disclosure provides drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-cleavable substrate conjugates, and to methods of treatment using them.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: May 11, 2010
    Assignee: Medarex, Inc.
    Inventors: Sanjeev Gangwar, Bilal Sufi
  • HUMANIZED ANTIBODIES TO INTERFERON ALPHA RECEPTOR-1 (IFNAR-1)
    Publication number: 20100104569
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 29, 2010
    Applicant: MEDAREX, INC.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • HUMAN ANTIBODIES THAT BIND CXCR4 AND USES THEREOF
    Publication number: 20100104508
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
    Type: Application
    Filed: October 1, 2007
    Publication date: April 29, 2010
    Applicant: Medarex, Inc.
    Inventors: Michelle Kuhne, Peter Brams, Dawn M. Tanamachi, Alan Korman, Josephine M. Cardarelli
  • HUMAN ANTIBODIES THAT BIND CD19 AND USES THEREOF
    Publication number: 20100104509
    Abstract: Human monoclonal antibodies that specifically bind to CD19 with high affinity are disclosed The antibodies are capable of internalizing into CD19-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies are also provided Also provided are methods for detecting CD19, as well as methods for treating cancers, such as B cell malignancies, for example, non-Hodgkin's lymphoma, chronic lymphocytic leukemias, follicular lymphomas, diffuse large cell lymphomas of B lineage, and multiple myelomas using an anti-CD 19 anti-body
    Type: Application
    Filed: December 13, 2007
    Publication date: April 29, 2010
    Applicant: Medarex, Inc.
    Inventors: David John King, Chetana Rao-Naik, Chin Pan, Josephine Cardarelli, Diann Blanset
  • CHEMICAL LINKERS AND CONJUGATES THEREOF
    Publication number: 20100092496
    Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
    Type: Application
    Filed: November 2, 2009
    Publication date: April 15, 2010
    Applicant: Medarex, Inc.
    Inventors: Sharon E. Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Killian Horgan, Zhi-Hong Li, Bilal Sufi
  • Prodrug compounds with isoleucine
    Patent number: 7696313
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: April 13, 2010
    Assignee: Medarex, Inc.
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • Chemical linkers and conjugates thereof
    Patent number: 7691962
    Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: April 6, 2010
    Assignee: Medarex, Inc.
    Inventors: Sharon E. Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Killian Horgan, Zhi-Hong Li, Bilal Sufi
  • IP-10 ANTIBODIES AND THEIR USES
    Publication number: 20100077497
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 27, 2009
    Publication date: March 25, 2010
    Applicant: MEDAREX, INC.
    Inventors: Shrikant DESHPANDE, Haichun HUANG, Mohan SRINIVASAN, Josephine M. CARDARELLI, Changyu WANG, David PASSMORE, Vangipuram RANGAN, Thomas E. LANE, Hans S. KEIRSTEAD, Michael T. LIU
  • Expression vector
    Patent number: 7674618
    Abstract: This invention provides nucleic acids and expression vectors, and host cells transformed with the same, for providing high expression of a desired polypeptide. Also provided are methods of using the expression vectors, nucleic acids, and host cells which have been modified by these compositions, for increasing expression of a gene encoding a desired polypeptide.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: March 9, 2010
    Assignee: Medarex, Inc.
    Inventor: Amelia Black
  • Human CTLA-4 Antibodies and Their Uses
    Publication number: 20100047244
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: September 22, 2009
    Publication date: February 25, 2010
    Applicant: Medarex, Inc.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Interferon alpha receptor 1 antibodies and their uses
    Patent number: 7662381
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: February 16, 2010
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND METHODS FOR USING ANTI-PTK7 ANTIBODIES
    Publication number: 20100034826
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
    Type: Application
    Filed: December 8, 2006
    Publication date: February 11, 2010
    Applicant: MEDAREX, INC
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20100034818
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: October 9, 2009
    Publication date: February 11, 2010
    Applicants: AMGEN, INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Monoclonal Antibodies Against CD30 Lacking in Fucosyl Residues
    Publication number: 20100021479
    Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: February 17, 2006
    Publication date: January 28, 2010
    Applicant: MEDAREX INC.
    Inventors: Josephine M. Cardarelli, Amelia Nancy Black
  • Peptidyl prodrugs and linkers and stabilizers useful therefor
    Patent number: RE41252
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: April 20, 2010
    Assignee: Medarex, Inc.
    Inventors: Howard P. Ng, Danny P. C. McGee, Guoxian Wu, Jimmie Moore, Zhi-Hong Li, Sanjeev Gangwar, Oliver L. Saunder, Irina Astafieva, Valeri Martichonok